Suki Just Raised $90 Million to Turn Its AI Scribe Into an AI Workforce for Clinics

The AI scribe business just had its biggest week of the year. Suki, the Redwood City startup whose software listens to doctor-patient conversations and drafts the clinical notes, has closed a $90 million Series E financing round, the company announced this week. The money marks a sharp turn in strategy: Suki is expanding past documentation into agentic AI, software that does the follow-up work itself, booking referrals, scheduling follow-ups, and handling prior authorizations.

The round was led by Healthier Capital, with Crosslink Capital and Hercules Capital joining as new investors, and participation from all of Suki's existing institutional backers, including Venrock, Flare Capital Partners, Hedosophia, Philips Ventures, and Zoom Ventures. As part of the financing, Healthier Capital partner Aman Mahajan, a physician with prior roles at UPMC and UCLA Health, will join Suki's board of directors.

From note-taker to workflow runner

Suki's pitch has always been about giving doctors their time back. Physicians spend hours each day on documentation and administrative tasks, work that contributes to burnout and squeezes the number of patients they can see. Suki's ambient clinical intelligence platform listens during the visit and turns the conversation into structured notes, orders, and coding, integrated across the major electronic health record systems.

The new capital is aimed at the next layer. CEO and founder Punit Soni said the company will use the money to scale its ambient clinical intelligence capabilities and add agentic capabilities on top of them. In practice, that means AI that does not just write up the visit but acts on it: drafting referrals, placing orders, scheduling follow-up appointments, and navigating the prior authorization maze that delays care.

Suki is expanding past documentation into agentic AI: software that does the follow-up work itself, booking referrals, scheduling follow-ups, and handling prior authorizations.

The timing is deliberate. Health systems are drowning in administrative backlog, and the prior authorization process in particular has become a political flashpoint, with insurers' approval delays linked to worse patient outcomes. If an AI agent can clear referrals and authorizations while the doctor moves on to the next patient, the economics of a clinic change fast.

The numbers behind the raise

Suki says demand for enterprise healthcare AI is accelerating sharply. Patient encounters supported by its platform grew more than 190 percent year over year in 2026. Revenue doubled in 2025 and is on track for similar growth this year, the company says, while revenue from its partner business has increased more than tenfold over the past two years.

Distribution is the engine. Suki now serves more than 450 healthcare organizations through its clinician-facing application, and more than 30 technology companies embed its AI into their own platforms, including Optum, Zoom, and athenahealth. The company plans to use part of the new funding to deepen those partnerships, turning the embedded-software channel into a second growth business alongside direct sales to health systems.

Last week the company also rolled out Ask, a feature that brings trusted clinical knowledge from Wolters Kluwer's UpToDate Expert AI directly into clinicians' workflows, a sign that the platform is becoming a broader work surface rather than a single-purpose tool.

Healthcare AI is having a funding moment

Suki is not alone. The ambient clinical intelligence market has become one of the most competitive corners of healthcare technology, and investors are writing big checks. This month, Australian startup Heidi raised $340 million, including a $100 million Series C led by Blackbird at a $900 million valuation. EliseAI raised $350 million at a $4 billion valuation for AI tools spanning healthcare and housing. Stockholm-based Tandem Health closed a $100 million Series B for an AI copilot that generates medical notes during consultations, and Healthleap raised $38 million for AI screening software.

The crowded field is both validation and risk. Every scribe company is racing to move up the stack from transcription to full workflow automation, and the winner may be decided less by who has the best language model than by who is already inside the health system's plumbing. Suki's pitch to investors is exactly that: 450 organizations, 30 embedded partners, and encounter volume growing nearly triple digits.

What this means for the business of care

For health systems, the calculation is straightforward: administrative work is one of the largest controllable costs in clinical operations, and physician burnout is a retention crisis. Software that genuinely removes hours of charting and paperwork is one of the easiest AI investments to justify, which is why ambient scribing went from experiment to standard vendor category in a few short years.

The harder question is where the value pools next. Documentation is table stakes; every serious competitor has it. The differentiator is what happens after the note is written. Suki is betting that agentic workflows, referrals, orders, scheduling, and prior authorizations handled by AI, are the feature set that turns a tool into infrastructure.

If the bet pays off, the company moves from being a scribe vendor to an operating layer for clinics. If it does not, it is still a fast-growing documentation business in a market expanding fast enough to carry several winners. Either way, the $90 million signals that the market for AI that does clinical paperwork is no longer about whether doctors will use it, but about who builds the fullest stack of what comes next.